Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 8:12:1597144.
doi: 10.3389/fmolb.2025.1597144. eCollection 2025.

Editorial: Therapeutic mechanism of osteosarcoma

Affiliations
Editorial

Editorial: Therapeutic mechanism of osteosarcoma

Siyi Chen et al. Front Mol Biosci. .
No abstract available

Keywords: CAR-T cell therapy; Wnt/β-catenin signaling; immunotherapy; metabolic reprogramming; osteosarcoma; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Therapeutic mechanism of osteosarcoma

Similar articles

References

    1. Chadha M., Huang P. H. (2022). Proteomic and metabolomic profiling in soft tissue sarcomas. Curr. Treat. Options Oncol. 23, 78–88. 10.1007/s11864-022-00947-3 - DOI - PMC - PubMed
    1. Conte F., Fiscon G., Sibilio P., Licursi V., Paci P. (2021). An overview of the computational models dealing with the regulatory ceRNA mechanism and ceRNA deregulation in cancer. Methods Mol. Biol. 2324, 149–164. 10.1007/978-1-0716-1503-4_10 - DOI - PubMed
    1. Piro G., Carbone C., Carbognin L., Pilotto S., Ciccarese C., Iacovelli R., et al. (2019). Revising PTEN in the era of immunotherapy: new perspectives for an old story. Cancers 11, 1525. 10.3390/cancers11101525 - DOI - PMC - PubMed
    1. Sabit H., Arneth B., Pawlik T. M., Abdel-Ghany S., Ghazy A., Abdelazeem R. M., et al. (2025). Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance. Pharm. (Basel) 18, 75. 10.3390/ph18010075 - DOI - PMC - PubMed
    1. Xu X., Liu C., Wang Y., Koivisto O., Zhou J., Shu Y., et al. (2021). Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv. Drug Deliv. Rev. 176, 113891. 10.1016/j.addr.2021.113891 - DOI - PubMed

Publication types

LinkOut - more resources